Citadel Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$83.7M Sell
600,300
-438,900
-42% -$61.5M 0.01% 937
2025
Q4
$128M Sell
1,039,200
-191,300
-16% -$23.2M 0.02% 712
2025
Q3
$137M Sell
1,230,500
-392,600
-24% -$44.6M 0.02% 663
2025
Q2
$180M Buy
1,623,100
+587,700
+57% +$62.5M 0.03% 451
2025
Q1
$116M Sell
1,035,400
-351,800
-25% -$36.3M 0.02% 606
2024
Q4
$128M Buy
1,387,200
+192,300
+16% +$17.3M 0.02% 604
2024
Q3
$100M Sell
1,194,900
-348,800
-23% -$26.6M 0.02% 697
2024
Q2
$106M Sell
1,543,700
-53,400
-3% -$3.56M 0.02% 654
2024
Q1
$117M Buy
1,597,100
+379,700
+31% +$29.2M 0.02% 611
2023
Q4
$98.6M Sell
1,217,400
-100,600
-8% -$7.83M 0.02% 687
2023
Q3
$98.8M Buy
1,318,000
+278,400
+27% +$21.4M 0.02% 633
2023
Q2
$80.1M Sell
1,039,600
-60,000
-5% -$4.79M 0.02% 753
2023
Q1
$91.2M Sell
1,099,600
-551,900
-33% -$45.7M 0.02% 671
2022
Q4
$142M Sell
1,651,500
-224,600
-12% -$17.8M 0.03% 485
2022
Q3
$116M Sell
1,876,100
-237,700
-11% -$15M 0.03% 531
2022
Q2
$131M Sell
2,113,800
-1,223,300
-37% -$75.7M 0.03% 437
2022
Q1
$198M Buy
3,337,100
+571,900
+21% +$36.6M 0.04% 343
2021
Q4
$201M Sell
2,765,200
-458,100
-14% -$31.6M 0.04% 345
2021
Q3
$225M Sell
3,223,300
-829,900
-20% -$58.3M 0.05% 306
2021
Q2
$279M Sell
4,053,200
-728,300
-15% -$48.6M 0.06% 223
2021
Q1
$309M Sell
4,781,500
-328,500
-6% -$21.2M 0.08% 170
2020
Q4
$298M Sell
5,110,000
-334,300
-6% -$20.2M 0.08% 161
2020
Q3
$344M Buy
5,444,300
+158,200
+3% +$11M 0.1% 102
2020
Q2
$407M Buy
5,286,100
+1,755,000
+50% +$134M 0.15% 61
2020
Q1
$264M Buy
3,531,100
+42,100
+1% +$2.91M 0.12% 90
2019
Q4
$227M Buy
3,489,000
+920,600
+36% +$60M 0.1% 147
2019
Q3
$163M Buy
2,568,400
+461,700
+22% +$30.2M 0.08% 212
2019
Q2
$142M Sell
2,106,700
-455,600
-18% -$30M 0.07% 262
2019
Q1
$167M Buy
2,562,300
+640,400
+33% +$42.6M 0.08% 190
2018
Q4
$120M Buy
1,921,900
+51,800
+3% +$3.62M 0.07% 268
2018
Q3
$144M Sell
1,870,100
-234,400
-11% -$17.7M 0.06% 280
2018
Q2
$149M Buy
2,104,500
+433,200
+26% +$30.6M 0.07% 238
2018
Q1
$126M Sell
1,671,300
-1,169,900
-41% -$93M 0.07% 237
2017
Q4
$204M Buy
2,841,200
+1,251,200
+79% +$95M 0.12% 135
2017
Q3
$129M Buy
1,590,000
+143,800
+10% +$11M 0.1% 174
2017
Q2
$102M Buy
1,446,200
+284,000
+24% +$18.9M 0.09% 219
2017
Q1
$78.9M Sell
1,162,200
-88,900
-7% -$6.25M 0.07% 261
2016
Q4
$89.6M Sell
1,251,100
-79,700
-6% -$5.92M 0.09% 197
2016
Q3
$105M Buy
1,330,800
+428,200
+47% +$34.8M 0.11% 155
2016
Q2
$75.3M Buy
902,600
+117,100
+15% +$10.4M 0.08% 208
2016
Q1
$72.2M Buy
785,500
+142,100
+22% +$12.8M 0.09% 194
2015
Q4
$65.1M Sell
643,400
-390,000
-38% -$40.6M 0.07% 296
2015
Q3
$101M Buy
1,033,400
+85,700
+9% +$9.52M 0.1% 198
2015
Q2
$111M Buy
947,700
+295,800
+45% +$32.3M 0.1% 212
2015
Q1
$64M Sell
651,900
-458,400
-41% -$46.5M 0.06% 373
2014
Q4
$105M Buy
1,110,300
+423,000
+62% +$43.7M 0.1% 190
2014
Q3
$73.2M Sell
687,300
-43,400
-6% -$4.25M 0.08% 266
2014
Q2
$60.6M Sell
730,700
-420,300
-37% -$32.7M 0.07% 299
2014
Q1
$81.6M Buy
1,151,000
+363,400
+46% +$28.5M 0.1% 216
2013
Q4
$59.2M Buy
787,600
+118,400
+18% +$8.24M 0.08% 293
2013
Q3
$42.1M Sell
669,200
-20,200
-3% -$1.21M 0.06% 380
2013
Q2
$35.3M Buy
+689,400
New +$35.9M 0.06% 373

Other funds holding GILD

Citadel Advisors's GILD Position: Q1 2026 in Review

Citadel Advisors increased its Gilead Sciences (GILD) stake by 2.4% in Q1 2026, buying an estimated $13.3M and bringing the position to 3,982,185 shares worth $555M. The position accounts for 0.09% of the portfolio, ranked #156.

Citadel Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $607M in Q2 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Citadel Advisors held 3,982,185 shares of Gilead Sciences worth $555M as of Q1 2026.
  • Citadel Advisors bought 94,665 Gilead Sciences shares in Q1 2026, an estimated $13.3M.
  • Gilead Sciences made up 0.09% of Citadel Advisors's portfolio in Q1 2026, its #156 holding.
  • Citadel Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Gilead Sciences position peaked at $607M in Q2 2025.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.